IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model.
Animals
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Cattle
Cell Extracts
/ administration & dosage
Cell Line, Tumor
Cyclophosphamide
/ administration & dosage
Doxorubicin
/ administration & dosage
Female
Humans
Immunologic Factors
/ administration & dosage
Leukocytes
/ immunology
Mammary Neoplasms, Experimental
/ drug therapy
Mice, Inbred BALB C
Triple Negative Breast Neoplasms
/ drug therapy
Tumor Microenvironment
/ drug effects
4T1
Breast cancer
IMMUNEPOTENT CRP (ICRP)
Immunotherapy
Treatment
Tumor microenvironment
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
29
09
2019
revised:
26
02
2020
accepted:
27
02
2020
pubmed:
17
3
2020
medline:
4
2
2021
entrez:
16
3
2020
Statut:
ppublish
Résumé
In 1889, Steven Paget postulated the theory that cancer cells require a permissive environment to grow. This permissive environment is known as the tumor microenvironment (TME) and nowadays it is evident that the TME is involved in the progression and response to therapy of solid cancer tumors. Triple-negative breast cancer is one of the most lethal types of cancer for women worldwide and chemotherapy remains the standard treatment for these patients. IMMUNEPOTENT CRP is a bovine dialyzable leukocyte extract with immunomodulatory and antitumor properties. The combination of chemotherapy and IMMUNEPOTENT CRP improves clinical parameters of breast cancer patients. In the current study, we aimed to evaluate the antitumor effect of doxorubicin/cyclophosphamide chemotherapy plus IMMUNEPOTENT CRP and its impact over the tumor microenvironment in a triple-negative breast cancer murine model. We evaluated CD8
Identifiants
pubmed: 32172064
pii: S0753-3322(20)30253-5
doi: 10.1016/j.biopha.2020.110062
pii:
doi:
Substances chimiques
Cell Extracts
0
Immunologic Factors
0
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110062Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.